Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

This is single center, open-label phase I/II, non-randomized study which will enroll patients with recurrent advanced hepatocellular carcinoma to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T in treating hepatocellular carcinoma.

Trial Details

NCT ID
NCT05323201
Phase
PHASE1 / PHASE2
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • fhB7H3.CAR-Ts
  • Fludarabine
  • Cyclophosphamide
Locations (sample)
  • Xuzhou, Jiangsu, China|34.20442,117.28386

Key Eligibility Criteria

  • Subjects should be 18-70 years old.
  • Subject has adequate performance status as defined by ECOG score of≤ 2.
  • Expected life expectancy is no less than 12 weeks.
  • Subjects must have histologically or cytologically confirmed unresectable, recurrent and / or metastatic hepatocellular carcinoma (HCC). And tumor …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →